Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Invernizzi

Showing results (391-400 of 420) with videos related to

Pageof 42
Sort By:
Journal of Hepatology|January 13, 2023
Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581]Heather J Cordell, James J Fryett, Kazuko Ueno, et al.
Journal of Hepatology|December 13, 2021
Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581]Heather J Cordell, James J Fryett, Kazuko Ueno, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Journal of Hepatology|May 25, 2021
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugsHeather J Cordell, James J Fryett, Kazuko Ueno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2025
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World DatabaseAlessandro Loglio, Ivan Gardini, Massimiliano Conforti, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Personalized Medicine|November 27, 2021
MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 SeverityClaudio Cappadona, Elvezia Maria Paraboschi, Nicole Ziliotto, et al.
Pageof 42

Showing results (391-400 of 420) with videos related to

Sort By:
Pageof 42
Journal of Hepatology|January 13, 2023
Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581]Heather J Cordell, James J Fryett, Kazuko Ueno, et al.
Journal of Hepatology|December 13, 2021
Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581]Heather J Cordell, James J Fryett, Kazuko Ueno, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Journal of Hepatology|May 25, 2021
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugsHeather J Cordell, James J Fryett, Kazuko Ueno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2025
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World DatabaseAlessandro Loglio, Ivan Gardini, Massimiliano Conforti, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Personalized Medicine|November 27, 2021
MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 SeverityClaudio Cappadona, Elvezia Maria Paraboschi, Nicole Ziliotto, et al.
Pageof 42